Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuroblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    130 result(s) found for: Neuroblastoma. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2005-005778-63 Sponsor Protocol Number: NB1-STI571 Start Date*: 2005-12-20
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Phase II study of Glivec (imatinib mesylate) in patients with advanced neuroblastoma
    Medical condition: High risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029260 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003832-96 Sponsor Protocol Number: ChIm-NB-PL Start Date*: 2021-10-13
    Sponsor Name:Jagiellonian University Medical College
    Full Title: Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease
    Medical condition: Recurrent or progression of neuroblastoma or neuroblastoma refractory to first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001811-16 Sponsor Protocol Number: PS21GAP Start Date*: 2022-12-19
    Sponsor Name:Princess Maxima Center for pediatric oncology
    Full Title: 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003606-33 Sponsor Protocol Number: PK 2008 03 Start Date*: 2009-01-15
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pilot study to investigate the feasibility of 13-cis-Retinoic acid pharmacokinetic monitoring in high-risk neuroblastoma
    Medical condition: High risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029260 Neuroblastoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002996-36 Sponsor Protocol Number: 15TETE04 Start Date*: 2021-06-23
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing som...
    Medical condition: Recurrent or refractory neuroblastoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005398-30 Sponsor Protocol Number: dopa Start Date*: 2013-05-03
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Diagnostic efficacy and prognostic method [18F] DOPA-PET/CT in study of neuroblastoma: comparison with 123I-MIBG scintigraphy
    Medical condition: patients wiht NB onset with high probability to return in stages 3 and 4 of the disease on the basis of the ultrasound images or TC. May also be included with the two-stage amplification of N-MYC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004864-69 Sponsor Protocol Number: HSJD-HR-NB-Ch14.18 Start Date*: 2014-05-21
    Sponsor Name:Fundació Sant Joan de Deu de Barcelona
    Full Title: Phase II single arm institutional study to assess Dinutuximab combined with the cytokines granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma...
    Medical condition: High-risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004862-15 Sponsor Protocol Number: MIITOP-0607 Start Date*: 2007-11-09
    Sponsor Name:Centre Oscar Lambret
    Full Title: Etude de Phase II de l'association Méta-lodobenzylguanidine I131 (MIBGI131) et Topotécan dans le traitement des neuroblastomes métastatiques réfractaires ou en rechute.
    Medical condition: Neuroblastome (métastaique réfractaire)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029260 Neuroblastoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002221-11 Sponsor Protocol Number: RHMCHI0811 Start Date*: 2017-09-28
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta in children with relapsed/refractory neuroblastoma
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000915-80 Sponsor Protocol Number: NB 2006 05 Start Date*: 2005-09-06
    Sponsor Name:University of Birmingham
    Full Title: A phase II study of Topotecan-Vincristine-Doxorubicin (TVD) in children with stage 4 neuroblastoma failing to respond to COJEC
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029260 Neuroblastoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004883-37 Sponsor Protocol Number: NB2015LR Start Date*: 2021-05-12
    Sponsor Name:University of Cologne
    Full Title: Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR)
    Medical condition: Neuroblastoma, low or intermediate risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004445-36 Sponsor Protocol Number: LuDO-N Start Date*: Information not available in EudraCT
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma.
    Medical condition: Primary refractory or relapsed high-risk neuroblastoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003130-27 Sponsor Protocol Number: 2015/2294 Start Date*: 2017-05-15
    Sponsor Name:Gustave Roussy
    Full Title: An international multicenter phase II randomized trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chem...
    Medical condition: Very High Risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008126 Cerebral neuroblastoma LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001042-18 Sponsor Protocol Number: J1O-MC-JZHD Start Date*: 2020-11-03
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
    Medical condition: Relapsed/Refractory Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001267-63 Sponsor Protocol Number: SIOPENRNET001 Start Date*: 2005-07-15
    Sponsor Name:St. Anna Kinderspital
    Full Title: Bridging study using ch14.18/CHO antibody in children with refractory neuroblastoma
    Medical condition: neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005104-25 Sponsor Protocol Number: INV500 Start Date*: 2018-01-02
    Sponsor Name:Nova BioPharma Limited
    Full Title: Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requi...
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029205 - Nervous system disorders 10029212 Nervous system neoplasms malignant NEC HLT
    20.0 10029205 - Nervous system disorders 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004481-34 Sponsor Protocol Number: Uni-Koeln-1694 Start Date*: 2015-03-12
    Sponsor Name:University of Cologne
    Full Title: RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL...
    Medical condition: Recurrent, progressive or newly diagnosed high risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001068-31 Sponsor Protocol Number: 2019/2894 Start Date*: 2019-09-24
    Sponsor Name:Gustave Roussy
    Full Title: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic p...
    Medical condition: Very High Risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029261 Neuroblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) SI (Ongoing) IT (Ongoing) GR (Ongoing) CZ (Ongoing) NO (Ongoing) BE (Ongoing) SE (Ongoing) SK (Ongoing) ES (Ongoing) DE (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) DK (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) AT (Completed) DE (Prematurely Ended) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003713-33 Sponsor Protocol Number: 70903 Start Date*: 2020-03-02
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: Diagnostic accuracy of neuroblastoma patient imaging with [18F]-mFBG PET-CT compared to [123]I-mIBG scanning
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA